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STAY FOR SCHIZOPHRENIA IN THE UNITED STATES
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1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
2Duke University Medical Center, Durham, NC, USA
OBJECTIVES: To assess the national trend and regional varia-
tions in the length of stay (LOS) and medical practices for schiz-
ophrenia in the United States. METHODS: Schizophrenia
inpatient care records were selected from the 1988 through 2000
National Inpatient Sample of Hospital Care Utilization Project
(HCUP), a database that approximates a 20% sample of all US
community hospitals. Using hospital and discharge sampling
weights, national level estimates were produced to demonstrate
the changes and patterns in LOS, medical practices, and associ-
ated demographic and clinical characteristics. RESULTS: The
national average LOS for schizophrenia was found to have
decreased from 16.22 days in year 1988 to 11.16 days in year
2000. Signiﬁcant drop in LOS was observed from 1994 to 1998,
but in all other years the changes were very small. The LOS
varied substantially across geographical areas. In year 2000, the
lowest LOS was 8.75 days in the Midwest, whereas in the North-
east LOS was nearly doubled at 16.18 days, and topped the
national level. This difference was also accompanied by a sharp
difference in medical practice between the two regions, that in
the Midwest, individual psychotherapy (ICD-9-CM procedure
code 9439) and electroshock therapy (code 9427) were the two
most commonly used principal procedures, accounting for 27%
and 15% respectively, whereas in the Northeast, psychiatric drug
therapy (code 9425) was most common (38%), followed by
other counseling (code 9449, 14%). In addition, there existed
some regional differences in demographic and clinical charac-
teristics. CONCLUSIONS: LOS for schizophrenia patients has
decreased considerably from year 1988 to 2000 and differed 
signiﬁcantly between different regions. These ﬁndings carry
important policy implications regarding the relative efﬁciency,
appropriateness and quality of hospital care in treating schizo-
phrenia patients. Further studies are warranted to assess the
patient health outcomes associated with the varied treatment
patterns.
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MISDIAGNOSIS OF BIPOLAR DISORDER AS 
UNIPOLAR DEPRESSION
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Bipolar disorder is frequently misdiagnosed as unipolar depres-
sion, in part, because of its episodic and cyclical nature. When
a patient presents with symptoms of depression, a history of
bipolar disorder precludes a unipolar depression diagnosis.
OBJECTIVE: The objective of this study was to examine the rate
that bipolar patients are misdiagnosed with unipolar depression
in current practice. METHODS: To examine patterns of diag-
nosis, the PharMetrics Integrated Outcomes Database of adju-
dicated medical and pharmaceutical claims for over 3 million
patients from 11 U.S. health plans was utilized. In this database,
3679 patients had two claims with ICD-9 diagnostic codes for
bipolar disorder (296.0, 296.1, 296.4–296.8) that were not
accompanied by a unipolar depression diagnostic code, age
between 10 and 64, and 1 year of continuous eligibility prior to
and following the initial bipolar diagnosis claim. RESULTS: In
the 12 months prior to their initial bipolar diagnosis, 14% of
patients had at least two claims for unipolar depression. In the
12 months following the initial bipolar diagnostic claim 32%
had at least two unipolar depression claims. When examining
only patients who were diagnosed with bipolar disorder during
an inpatients hospital stay, 47% were diagnosed with unipolar
depression in the following 12 months. CONCLUSION: A dis-
concertingly high proportion of bipolar patients were diagnosed
with unipolar depression following their initial bipolar diag-
noses. These results suggest that greater physician education 
is needed regarding bipolar disorder and the importance of
obtaining a history when patients present with symptoms of
depression.
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OBJECTIVES: This study compares switching and discontinua-
tion rates for patients who had already switched from ﬂuoxetine
to other branded selective serotonin reuptake inhibitors (SSRIs).
METHODS: Retrospective analysis of claims in an administra-
tive database from January 1, 1999 to June 30, 2002. Claims for
patients on ﬂuoxetine who switched to sertraline, paroxetine or
citalopram were analyzed to compare rates of discontinuation or
second switch to another SSRI. We used Cox proportional
models and life table survival curves. Deﬁnition of switching or
discontinuation was based on SSRI reﬁll within 15 days or 2 days
supply. RESULTS: Paroxetine patients (N = 217) were signiﬁ-
cantly more likely to switch (HR = 1.47, p = 0.033) than ser-
traline patients (N = 227). The likelihood of switching (HR =
0.98, p = 0.917) was not signiﬁcantly different for patients on
citalopram (N = 291) than on sertraline. Patients were as likely
to discontinue when on sertraline (N = 324), paroxetine (N =
293) or citalopram (N = 437). Average number of distinct drugs
(p = 0.0005) and average number of claims (p = 0.0006) were
signiﬁcant predictor of discontinuation, while age, gender and
co-payment were not. CONCLUSIONS: Patients on ﬂuoxetine
who had switched to paroxetine were signiﬁcantly more likely
to switch again than those who had switched to sertraline. The
likelihood of discontinuation was similar among patients on 
sertraline, paroxetine or citalopram.
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OBJECTIVES: Prior research documents that discontinuation
rates among selective serotonin reuptake inhibitor (SSRI) users
are high, but little is known about the likelihood of reﬁlling at
least one prescription. This study compares rates of ﬁrst reﬁlls
across SSRIs that remain on patent. METHODS: This retro-
spective cohort study used an administrative database from
January 1, 1999 to June 30, 2002. Patients were followed up to
6 months after the ﬁrst branded SSRIs. “Reﬁll” was deﬁned as
reﬁlling the ﬁrst prescription for SSRIs of interest within 15 days
or 1.5 times days supply. Logistic regression and sensitivity
analyses examined the impact of age, gender, and co-payment as
covariates. RESULTS: Based on descriptive analyses, sertraline,
patients (N = 5590; 54.70% reﬁll; p = 0.0001) or citalopram
patients (N = 4124; 54.49% reﬁll; p = 0.0008) were more likely
to have a reﬁll than paroxetine patients (N = 5201; 50.99%
reﬁll). These results were consistent with the logistic regressions
where covariates were signiﬁcant at the p < 0.10 but not the p
